Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price upped by analysts at B. Riley from $3.00 to $4.00 in a research report issued on Monday. The firm presently has a “neutral” rating on the biotechnology company’s stock. B. Riley’s price target would indicate a potential downside of 28.44% from the stock’s current price.

A number of other analysts also recently commented on the company. Cantor Fitzgerald set a $5.00 price objective on Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday. ValuEngine upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 18th. Finally, Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective for the company in a research report on Monday, November 27th. Five investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $4.13.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $5.59 on Monday. The company has a quick ratio of 3.63, a current ratio of 3.63 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $6.75. The company has a market capitalization of $485.14, a P/E ratio of -11.89 and a beta of 2.53.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. The firm had revenue of $8.71 million during the quarter, compared to the consensus estimate of $7.32 million. sell-side analysts expect that Arrowhead Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

In related news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the completion of the transaction, the chief operating officer now owns 948,356 shares in the company, valued at approximately $3,499,433.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of ARWR. First Manhattan Co. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $11,707,000. ING Groep NV bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $3,500,000. Allianz Asset Management GmbH bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $1,958,000. Alps Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $305,000. Finally, Acadian Asset Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 1,177.7% during the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after buying an additional 66,055 shares during the period. Institutional investors and hedge funds own 20.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: “B. Riley Raises Arrowhead Pharmaceuticals (ARWR) Price Target to $4.00” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2018/02/12/b-riley-raises-arrowhead-pharmaceuticals-arwr-price-target-to-4-00.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.